The 7 major varicose veins markets are expected to exhibit a CAGR of 5.5% during 2025-2035.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2035
|
Historical Years
|
2019-2024
|
Market Growth Rate 2025-2035 | 5.5% |
The varicose veins market has been comprehensively analyzed in IMARC's new report titled "Varicose Veins Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Varicose veins refer to a common condition characterized by enlarged, twisted, and swollen veins that usually appear on the legs and feet. These veins can be blue, purple, or red in color and are often visible through the skin. Some of the associated symptoms are bulging veins on the legs, dark purple or blue discoloration of the veins, aching or throbbing pain in the legs, a feeling of heaviness in the legs, swelling in the ankles and feet, itching or irritation around the affected veins, cramping or restless legs, etc. In many instances, varicose veins can lead to various complications, such as skin changes like dryness, thickening, inflammation, ulcers or sores, etc. The diagnosis of the condition typically involves a combination of medical history assessment, physical examination, and diagnostic tests. A physical exam may include inspecting and palpating the affected areas to identify the appearance of varicose veins, check for signs of complications, and evaluate blood flow. Various diagnostic procedures, such as Doppler ultrasound, may be performed to determine the functioning of the veins and locate any underlying vein abnormalities or blood clots.
The increasing cases of weakened or damaged valves within the veins, which disrupt the normal flow of blood, are primarily driving the varicose veins market. Furthermore, the rising prevalence of numerous associated risk factors, such as hormonal fluctuations, pregnancy, genetic predisposition, advancing age, prolonged sitting or standing, prior vein damage, etc., is creating a positive outlook for the market. Apart from this, the widespread adoption of sclerotherapy, which involves injecting a sclerosing solution directly into the affected veins, causing them to collapse and fade over time, is also bolstering the market growth. Moreover, the escalating utilization of compression stockings, since they help in promoting blood flow, thereby pushing the blood upwards towards the heart and reducing the pooling of blood in the veins, is acting as another significant growth-inducing factor. Additionally, the inflating application of endovenous thermal ablation on account of its several associated benefits, such as less post-procedural pain, decreased scarring, and a faster recovery compared to traditional surgical procedures like vein stripping, is expected to drive the varicose veins market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the varicose veins market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for varicose veins and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the varicose veins market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current varicose veins marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Varithena (Polidocanol) | BTG |
Asclera (Polidocanol) | BioForm Medical/Chemische Fabrik Kreussler & Co |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Varicose Veins: Current Treatment Scenario, Marketed Drugs and Emerging Therapies